Liver expression of Nrf2-related genes in different liver diseases

Hepatobiliary and Pancreatic Diseases International

Volumn 14, Issue 5, 2015, Pages 485-491

  Cheng, Ming Liang ^a   Lu, Yuan Fu ^b   Chen, Hong ^c   Shen, Zhong Yang ^c   Liu, Jie ^b  

^a GUIZHOU MEDICAL UNIVERSITY   (China)

^b ZUNYI MEDICAL UNIVERSITY   (China)

^c GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

Author keywords

Cirrhosis; End stage liver disease; Hepatocellular carcinoma; Nrf2 related gene expression

Indexed keywords

GLUTAMATE CYSTEINE LIGASE; HEME OXYGENASE 1; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MESSENGER RNA; PEROXIREDOXIN 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TRANSCRIPTION FACTOR NRF2; GCLC PROTEIN, HUMAN; GLUTAMATE-CYSTEINE LIGASE MODIFIER SUBUNIT, HUMAN; HMOX1 PROTEIN, HUMAN; KEAP1 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; NQO1 PROTEIN, HUMAN; PEROXIREDOXIN; PRDX1 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CONTROLLED STUDY; END STAGE LIVER DISEASE; ENZYME ACTIVE SITE; FEMALE; GLUTATHIONE METABOLISM; HEPATITIS B; HEPATITIS B VIRUS RELATED CIRRHOSIS; HUMAN; HUMAN TISSUE; LIVER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; VERY ELDERLY; COMPLICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; SIGNAL TRANSDUCTION; VIROLOGY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; END STAGE LIVER DISEASE; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLUTAMATE-CYSTEINE LIGASE; HEME OXYGENASE-1; HEPATITIS B, CHRONIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; LIVER CIRRHOSIS; LIVER CIRRHOSIS, ALCOHOLIC; LIVER NEOPLASMS; MALE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); NF-E2-RELATED FACTOR 2; PEROXIREDOXINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84944032744     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-3872(15)60425-8     Document Type: Article

References (41)

1. Klaassen CD, Reisman SA. Nrf2 the rescue: effects of the an-tioxidative/electrophilic response on the liver. Toxicol Appl Pharmacol 2010;244:57-65.
2. Liu J, Wu KC, Lu YF, Ekuase E, Klaassen CD. Nrf2 protection against liver injury produced by various hepatotoxicants. Oxid Med Cell Longev 2013;2013:305861.
3. Aleksunes LM, Manautou JE. Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease. Toxicol Pathol 2007;35:459-473.
4. Shin SM, Yang JH, Ki SH. Role of the Nrf2-ARE pathway in liver diseases. Oxid Med Cell Longev 2013;2013:763257.
5. Yang JJ, Tao H, Huang C, Li J. Nuclear erythroid 2-related factor 2: a novel potential therapeutic target for liver fbrosis. Food Chem Toxicol 2013;59:421-427.
6. Itoh K, Mimura J, Yamamoto M. Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid Redox Signal 2010;13:1665-1678.
7. Taguchi K, Motohashi H, Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 2011;16:123-140.
8. Wu KC, Cui JY, Klaassen CD. Effect of graded Nrf2 activation on phase-I and-II drug metabolizing enzymes and transporters in mouse liver. PLoS One 2012;7:e39006.
9. Wang YP, Cheng ML, Zhang BF, Mu M, Zhou MY, Wu J, et al. Effect of blueberry on hepatic and immunological functions in mice. Hepatobiliary Pancreat Dis Int 2010;9:164-168.
10. Hardwick RN, Fisher CD, Canet MJ, Lake AD, Cherrington NJ. Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 2010;38:2293-2301.
11. Kawata K, Kobayashi Y, Souda K, Kawamura K, Sumiyoshi S, Takahashi Y, et al. Enhanced hepatic Nrf2 activation after ur-sodeoxycholic acid treatment in patients with primary biliary cirrhosis. Antioxid Redox Signal 2010;13:259-268.
12. Takahashi Y, Kobayashi Y, Kawata K, Kawamura K, Sumiyoshi S, Noritake H, et al. Does hepatic oxidative stress enhance activation of nuclear factor-E2-related factor in patients with nonalcoholic steatohepatitis? Antioxid Redox Signal 2014;20: 538-543.
13. Kurzawski M, Dziedziejko V, Urasinska E, Post M, Wójcicki M, Mietkiewski J, et al. Nuclear factor erythroid 2-like 2 (Nrf2) expression in end-stage liver disease. Environ Toxicol Pharmacol 2012;34:87-95.
14. Chen H, Shen ZY, Xu W, Fan TY, Li J, Lu YF, et al. Expression of P450 and nuclear receptors in normal and end-stage Chinese livers. World J Gastroenterol 2014;20:8681-8690.
15. Wu KC, Liu JJ, Klaassen CD. Nrf2 activation prevents cadmium-induced acute liver injury. Toxicol Appl Pharmacol 2012;263:14-20.
16. Wu KC, Liu J, Klaassen CD. Role of Nrf2 in preventing etha-nol-induced oxidative stress and lipid accumulation. Toxicol Appl Pharmacol 2012;262:321-329.
17. Lu YF, Liu J, Wu KC, Klaassen CD. Protection against phalloi-din-induced liver injury by oleanolic acid involves Nrf2 activation and suppression of Oatp1b2. Toxicol Lett 2014;232:326-332.
18. Enomoto A, Itoh K, Nagayoshi E, Haruta J, Kimura T, O'Connor T, et al. High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol Sci 2001;59:169-177.
19. Xu W, Hellerbrand C, Köhler UA, Bugnon P, Kan YW, Werner S, et al. The Nrf2 transcription factor protects from toxin-induced liver injury and fbrosis. Lab Invest 2008;88:1068-1078.
20. Jiang T, Huang Z, Chan JY, Zhang DD. Nrf2 protects against As(III)-induced damage in mouse liver and bladder. Toxicol Appl Pharmacol 2009;240:8-14.
21. Liu F, Ichihara S, Valentine WM, Itoh K, Yamamoto M, Sheik Mohideen S, et al. Increased susceptibility of Nrf2-null mice to 1-bromopropane-induced hepatotoxicity. Toxicol Sci 2010;115: 596-606.
22. Lamlé J, Marhenke S, Borlak J, von Wasielewski R, Eriksson CJ, Geffers R, et al. Nuclear factor-eythroid 2-related factor 2 prevents alcohol-induced fulminant liver injury. Gastroenterology 2008;134:1159-1168.
23. Zhang YK, Yeager RL, Tanaka Y, Klaassen CD. Enhanced expression of Nrf2 in mice attenuates the fatty liver produced by a methionine-and choline-defcient diet. Toxicol Appl Pharmacol 2010;245:326-334.
24. Sugimoto H, Okada K, Shoda J, Warabi E, Ishige K, Ueda T, et al. Deletion of nuclear factor-E2-related factor-2 leads to rapid onset and progression of nutritional steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol 2010;298:G283-294.
25. Chowdhry S, Nazmy MH, Meakin PJ, Dinkova-Kostova AT, Walsh SV, Tsujita T, et al. Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. Free Radic Biol Med 2010;48: 357-371.
26. Wang C, Cui Y, Li C, Zhang Y, Xu S, Li X, et al. Nrf2 deletion causes "benign" simple steatosis to develop into nonalcoholic steatohepatitis in mice fed a high-fat diet. Lipids Health Dis 2013;12:165.
27. Bataille AM, Manautou JE. Nrf2: a potential target for new therapeutics in liver disease. Clin Pharmacol Ther 2012;92:340-348.
28. Okada K, Warabi E, Sugimoto H, Horie M, Tokushige K, Ueda T, et al. Nrf2 inhibits hepatic iron accumulation and counteracts oxidative stress-induced liver injury in nutritional steatohepa-titis. J Gastroenterol 2012;47:924-935.
29. Zhou R, Lin J, Wu D. Sulforaphane induces Nrf2 and protects against CYP2E1-dependent binge alcohol-induced liver steato-sis. Biochim Biophys Acta 2014;1840:209-218.
30. Yoo NJ, Kim HR, Kim YR, An CH, Lee SH. Somatic mutations of the KEAP1 gene in common solid cancers. Histopathology 2012;60:943-952.
31. Aleksunes LM, Goedken M, Manautou JE. Up-regulation of NAD(P)H quinone oxidoreductase 1 during human liver injury. World J Gastroenterol 2006;12:1937-1940.
32. Belinsky M, Jaiswal AK. NAD(P)H: quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev 1993;12:103-117.
33. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD. Dual roles of Nrf2 in cancer. Pharmacol Res 2008;58:262-270.
34. Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 2008;29:1235-1243.
35. Sass G, Barikbin R, Tiegs G. The multiple functions of heme oxygenase-1 in the liver. Z Gastroenterol 2012;50:34-40.
36. Luo YH, Li ZD, Liu LX, Dong GH. Pretreatment with erythro-poietin reduces hepatic ischemia-reperfusion injury. Hepato-biliary Pancreat Dis Int 2009;8:294-299.
37. Zou C, Zhang H, Li Q, Xiao H, Yu L, Ke S, et al. Heme oxy-genase-1: a molecular brake on hepatocellular carcinoma cell migration. Carcinogenesis 2011;32:1840-1848.
38. Caballero F, Meiss R, Gimenez A, Batlle A, Vazquez E. Immu-nohistochemical analysis of heme oxygenase-1 in preneoplastic and neoplastic lesions during chemical hepatocarcinogenesis. Int J Exp Pathol 2004;85:213-222.
39. Aguilar-Melero P, Prieto-álamo MJ, Jurado J, Holmgren A, Pu-eyo C. Proteomics in HepG2 hepatocarcinoma cells with stably silenced expression of PRDX1. J Proteomics. 2013;79:161-171.
40. Pi J, Freeman ML, Yamamoto M. Nrf2 in toxicology and pharmacology: the good, the bad and the ugly? Toxicol Appl Pharmacol 2010;244:1-3.
41. Yates MS, Kensler TW. Keap1 eye on the target: chemopreven-tion of liver cancer. Acta Pharmacol Sin 2007;28:1331-1342.